FIT Level 2 – Intermediate

Since the start of the Covid-19 pandemic supply contracts have been under the spotlight as never before. Manufacturing deals have been closed between major pharma companies in record times, but not surprisingly as often happens for novel products, supply difficulties have arisen.

The AstraZeneca team will share their insights and experiences in this critical area of business.

Presented by:

Brian Dell, Operations BD Director

Nidhi Jain, Director Operations Procurement

Adam McArthur, Assistant General Counsel, Digital, IT & Operations

Mike Stiles, Operations BD Director

Presented by

Roger Davies, former MSc Finance Tutor

Objective
This workshop studies the financial statements of a stock market listed Biotech firm and a Pharmaceutical company. You will learn how to extract and understand information to assist in structuring your deals.

Work Shop Content
1. How to find useful financial information on public and private companies

2. Understand financial reporting elements
•Profit & Loss account
•Balance sheet
•Cash statement

3. How to analyse financial information to support deals:
•Supply agreement
•Licensing deal
•Product Acquisition

Presented by

• Kay Tait, Senior Transaction Director, Business Development Operations, AstraZeneca
• Umaima Ahamd, Associate Transaction Director, Business Development Operations, AstraZeneca
• Jarlath Astin, Senior Legal Counsel, AstraZeneca
• Dan Briody, Deal Finance Director, AstraZeneca

Learning Outcomes

• Understand the pros and cons of using a term sheet
• Understand the parts of a term sheet that are typically binding or non-binding
• Understand how deal structure and stage influences term sheet content
• Understand the typical content of a term sheet
• Understand financing structures typically seen across life science BD deals
• Apply your understanding through reviewing a term sheet for an in-licensing transaction
• Be able to construct and prioritise an issues list

It will also cover the ways in which a seller / licensor can limit its liability under the contract as a further way of apportioning risk between the contractual parties.

Sarah Moyles, Shareholder, GreenbergTraurig
&
Henrietta Walker, Shareholder, GreenbergTraurig